[1] Alevizakos M, Karanika S, Detsis M, Mylonakis E. Colonisation with extended-spectrum beta-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016; 48 (6):647-54. doi:10.1016/j.ijantimicag.2016.08.021.
[2] Gudiol C, Aguado JM, Carratala J. Bloodstream infections in patients with solid tumors. Virulence. 2016; 7 (3):298-308. doi:10.1080/21505594.2016.1141161.
[3] Zembower TR. Epidemiology of Infections in Cancer Patients. In: Stosor V, Zembower TR. Infectious Complications in Cancer Patients, Cham: Springer International Publishing; 2014, p. 43-89.
[4] Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. The Lancet Oncology. 2009; 10 (6):589-97. doi:https://doi.org/10.1016/S1470-2045(09)70069-5.
[5] Brand JS, Colzani E, Johansson ALV, et al. Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. J Infect. 2016; 72 (6):650-8. doi:10.1016/j.jinf.2016.04.003.
[6] Dimomicronpoulos G, Rovina N, Patrani M, et al. Past history of stage I/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group. BMC Infect Dis. 2019; 19 (1):831. doi:10.1186/s12879-019-4448-7.
[7] Zinner SH. Changing Epidemiology of Infections in Patients with Neutropenia and Cancer: Emphasis on Gram-Positive and Resistant Bacteria. Clinical Infectious Diseases. 1999; 29 (3):490-4. doi:10.1086/598620.
[8] Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current Trends in the Epidemiology of Nosocomial Bloodstream Infections in Patients with Hematological Malignancies and Solid Neoplasms in Hospitals in the United States. Clinical Infectious Diseases. 2003; 36 (9):1103-10. doi:10.1086/374339.
[9] Gudiol C, Bodro M, Simonetti A, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. 2013; 19 (5):474-9. doi:10.1111/j.1469-0691.2012.03879.x.
[10] Xiao T, Yang K, Zhou Y, et al. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to 2016. Antimicrob Resist Infect Control. 2019; 8:144. doi:10.1186/s13756-019-0599-y.
[11] Cattaneo C, Antoniazzi F, Casari S, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol. 2012; 91 (8):1299-304. doi:10.1007/s00277-012-1424-3.
[12] Pouch SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017; 8 (4):391-402. doi:10.1080/21505594.2016.1213472.
[13] Katip W, Uitrakul S, Oberdorfer P. Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients. Infect Drug Resist. 2017; 10:293-8. doi:10.2147/IDR.S144314.
[14] Gudiol C, Carratala J. Antibiotic resistance in cancer patients. Expert Rev Anti Infect Ther. 2014; 12 (8):1003-16. doi:10.1586/14787210.2014.920253.
[15] Perdikouri EIA, Arvaniti K, Lathyris D, et al. Infections Due to Multidrug-Resistant Bacteria in Oncological Patients: Insights from a Five-Year Epidemiological and Clinical Analysis. Microorganisms. 2019; 7 (9). doi:10.3390/microorganisms7090277.
[16] Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52 (4):427-31. doi:10.1093/cid/ciq147.
[17] Kochanek M, Schalk E, von Bergwelt-Baildon M, et al. Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2019; 98 (5):1051-69. doi:10.1007/s00277-019-03622-0.
[18] Heinz WJ, Buchheidt D, Christopeit M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol. 2017; 96 (11):1775-92. doi:10.1007/s00277-017-3098-3.
[19] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases. 1987; 40 (5):373-83. doi:https://doi.org/10.1016/0021-9681(87)90171-8.
[20] Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother. 2011; 66 (3):657-63. doi:10.1093/jac/dkq494.
[21] Zinn. CS, Westh. H, Rosdahl. VT. An International Multicenter Study of Antimicrobial Resistance and Typing of Hospital Staphylococcus aureus Isolates from 21 Laboratories in 19 Countries or States. Microbial Drug Resistance. 2004; 10 (2):160-8. doi:10.1089/1076629041310055.
[22] Palacios-Baena ZR, Gutierrez-Gutierrez B, De Cueto M, et al. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2017; 72 (3):906-13. doi:10.1093/jac/dkw513.
[23] Chen CY, Tien FM, Sheng WH, et al. Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008-2013. Int J Antimicrob Agents. 2017; 49 (3):272-81. doi:10.1016/j.ijantimicag.2016.11.009.
[24] Puerta-Alcalde P, Cardozo C, Suarez-Lledo M, et al. Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies. Clin Microbiol Infect. 2019; 25 (4):447-53. doi:10.1016/j.cmi.2018.07.026.
[25] Biehl LM, Schmidt-Hieber M, Liss B, Cornely OA, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective. Crit Rev Microbiol. 2016; 42 (1):1-16. doi:10.3109/1040841X.2013.875515.
[26] Freire MP, Pierrotti LC, Filho HH, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients. Eur J Clin Microbiol Infect Dis. 2015; 34 (2):277-86. doi:10.1007/s10096-014-2233-5.
[27] Marin M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratala J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014; 93 (3):143-9. doi:10.1097/MD.0000000000000026.
[28] Nazer LH, Kharabsheh A, Rimawi D, Mubarak S, Hawari F. Characteristics and Outcomes of Acinetobacter baumannii Infections in Critically Ill Patients with Cancer: A Matched Case-Control Study. Microb Drug Resist. 2015; 21 (5):556-61. doi:10.1089/mdr.2015.0032.
[29] Moghnieh R, Estaitieh N, Mugharbil A, et al. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis. Front Cell Infect Microbiol. 2015; 5:11. doi:10.3389/fcimb.2015.00011.
[30] Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nature Reviews Immunology. 2009; 9 (5):377-84. doi:10.1038/nri2530.
[31] Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012; 18 (1):54-60. doi:10.1111/j.1469-0691.2011.03478.x.
[32] Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect. 2013; 83 (4):307-13. doi:10.1016/j.jhin.2012.10.012.
[33] Fraenkel-Wandel Y, Raveh-Brawer D, Wiener-Well Y, Yinnon AM, Assous MV. Mortality due to blaKPC Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother. 2016; 71 (4):1083-7. doi:10.1093/jac/dkv414.
[34] Zhang LN, Tang J, Lan XW, OuYang PY, Xie FY. Pretreatment anemia and survival in nasopharyngeal carcinoma. Tumour Biol. 2016; 37 (2):2225-31. doi:10.1007/s13277-015-4042-6.
[35] Ashour HM, El-Sharif A. Species distribution and antimicrobial susceptibility of gram-negative aerobic bacteria in hospitalized cancer patients. J Transl Med. 2009; 7:14. doi:10.1186/1479-5876-7-14.
[36] Huang CC, Wu CJ, Wang LR, et al. Antimicrobial susceptibility of bacteremic isolates from cancer patients with or without neutropenia at a medical center in southern Taiwan. J Microbiol Immunol Infect. 2011; 44 (5):376-81. doi:10.1016/j.jmii.2011.01.035.